Last reviewed · How we verify
Adapalene 0.3% / BPO 2.5% gel
Adapalene is a retinoid that normalizes skin cell differentiation and reduces inflammation, while benzoyl peroxide provides antimicrobial activity against acne-causing bacteria.
Adapalene is a retinoid that normalizes skin cell differentiation and reduces inflammation, while benzoyl peroxide provides antimicrobial activity against acne-causing bacteria. Used for Acne vulgaris.
At a glance
| Generic name | Adapalene 0.3% / BPO 2.5% gel |
|---|---|
| Also known as | Epiduo Forte / Tactupump gel |
| Sponsor | Galderma R&D |
| Drug class | Retinoid + peroxide combination |
| Target | Retinoic acid receptors (adapalene); bacterial cell membranes and proteins (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Adapalene binds to retinoic acid receptors to regulate gene expression, reducing comedone formation and normalizing follicular keratinization. Benzoyl peroxide generates reactive oxygen species that kill Cutibacterium acnes and reduce bacterial lipase production. Together, they provide complementary anti-inflammatory and antimicrobial effects for acne treatment.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Dryness
- Peeling
- Irritation
- Photosensitivity
Key clinical trials
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (PHASE4)
- Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adapalene 0.3% / BPO 2.5% gel CI brief — competitive landscape report
- Adapalene 0.3% / BPO 2.5% gel updates RSS · CI watch RSS
- Galderma R&D portfolio CI